Abstract
Mild cognitive impairment (MCI) could be an auspicious candidate for an early marker of a beginning dementia. However, although MCI is accepted as a heterogeneous condition by now, performance testing or diagnosis is often based on a limited number of cognitive tests. Furthermore, there is still disagreement about the necessity to include subjective cognitive complaints as a diagnostic criterion. The current study intends to examine the character of MCI when diagnosis is based upon multiple cognitive domains and does not require the presence of subjective complaints. 130 subjects from the HelMA (Helmholtz Alliance for Mental Health in an Ageing Society) longitudinal study completed a comprehensive neuropsychological test-battery and were diagnosed as either normally-ageing controls or patients with MCI. The prevalence rate of MCI was as high as 46.2%, hereby exceeding most estimates of other studies. Patients with MCI performed worse than controls in each of the 29 administered tests with memory being the predominant impaired cognitive domain. Surprisingly, there was no single patient with a purely non-amnestic impairment, considerably contradicting hitherto existing studies. The rather different distribution of impairment and prevalence rate emphasizes the demand of testbatteries including all cognitive domains so that inferences about MCI are as all-encompassing as possible.
Keywords: Alzheimer’s disease, dementia, diagnosis, memory, mild cognitive impairment, neuropsychological assessment.
Current Alzheimer Research
Title:Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment
Volume: 10 Issue: 10
Author(s): E.I. Drexler, B. Voss, K. Amunts, F. Schneider and U. Habel
Affiliation:
Keywords: Alzheimer’s disease, dementia, diagnosis, memory, mild cognitive impairment, neuropsychological assessment.
Abstract: Mild cognitive impairment (MCI) could be an auspicious candidate for an early marker of a beginning dementia. However, although MCI is accepted as a heterogeneous condition by now, performance testing or diagnosis is often based on a limited number of cognitive tests. Furthermore, there is still disagreement about the necessity to include subjective cognitive complaints as a diagnostic criterion. The current study intends to examine the character of MCI when diagnosis is based upon multiple cognitive domains and does not require the presence of subjective complaints. 130 subjects from the HelMA (Helmholtz Alliance for Mental Health in an Ageing Society) longitudinal study completed a comprehensive neuropsychological test-battery and were diagnosed as either normally-ageing controls or patients with MCI. The prevalence rate of MCI was as high as 46.2%, hereby exceeding most estimates of other studies. Patients with MCI performed worse than controls in each of the 29 administered tests with memory being the predominant impaired cognitive domain. Surprisingly, there was no single patient with a purely non-amnestic impairment, considerably contradicting hitherto existing studies. The rather different distribution of impairment and prevalence rate emphasizes the demand of testbatteries including all cognitive domains so that inferences about MCI are as all-encompassing as possible.
Export Options
About this article
Cite this article as:
Drexler E.I., Voss B., Amunts K., Schneider F. and Habel U., Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment, Current Alzheimer Research 2013; 10 (10) . https://dx.doi.org/10.2174/15672050113109990014
DOI https://dx.doi.org/10.2174/15672050113109990014 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Current Alzheimer Research Magnesium as a Neuroprotective Agent in Cerebral Ischemia
Current Medicinal Chemistry - Central Nervous System Agents Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Targets of Antidementive Therapy: Drugs with a Specific Pharmacological Mechanism of Action
Current Pharmaceutical Design Understanding Healthy Protective Mechanisms Against Old Age
Current Aging Science Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
Letters in Drug Design & Discovery Elimination of the Causes of Poor Sleep Underlying Delirium is a Basic Strategy to Prevent Delirium
Current Molecular Pharmacology Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Editorial: Advances in Alzheimer Therapy: Something Old, Something New, Something Borrowed, Something Blue
Current Alzheimer Research Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage
Current Alzheimer Research Tau Oligomerization: A Role for Tau Aggregation Intermediates Linked to Neurodegeneration
Current Alzheimer Research Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Current Alzheimer Research PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design